Trial · NCT01620255
Results by group304
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 304
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants in Clinical Remission at Week 12 | Placebo | Centrally read | 2.7 | 90% Confidence Interval 0.7 to 7.6 | percentage of participants |
| Percentage of Participants in Clinical Remission at Week 12 | PF-00547659 7.5 mg | Centrally read | 11.3 | 90% Confidence Interval 5.7 to 18.8 | percentage of participants |
| Percentage of Participants in Clinical Remission at Week 12 | PF-00547659 22.5 mg | Centrally read | 16.7 | 90% Confidence Interval 9.9 to 25.4 | percentage of participants |
| Percentage of Participants in Clinical Remission at Week 12 | PF-00547659 75 mg | Centrally read | 15.5 | 90% Confidence Interval 9.5 to 23.6 | percentage of participants |
| Percentage of Participants in Clinical Remission at Week 12 | PF-00547659 225 mg | Centrally read | 5.7 | 90% Confidence Interval 2.5 to 12.5 | percentage of participants |
| Percentage of Participants in Clinical Remission at Week 12 | Placebo | Locally read | 5.5 | 90% Confidence Interval 2.4 to 12.0 | percentage of participants |
| Percentage of Participants in Clinical Remission at Week 12 | PF-00547659 7.5 mg | Locally read | 14.1 | 90% Confidence Interval 7.8 to 22.0 | percentage of participants |
| Percentage of Participants in Clinical Remission at Week 12 | PF-00547659 22.5 mg | Locally read | 23.6 | 90% Confidence Interval 15.6 to 33.1 | percentage of participants |
| Percentage of Participants in Clinical Remission at Week 12 | PF-00547659 75 mg | Locally read | 18.3 | 90% Confidence Interval 11.9 to 27.1 | percentage of participants |
| Percentage of Participants in Clinical Remission at Week 12 | PF-00547659 225 mg | Locally read | 12.9 | 90% Confidence Interval 7.3 to 21.1 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | Placebo | Centrally read (n=73,71,72,71,70) | 28.8 | 90% Confidence Interval 20.2 to 37.8 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | PF-00547659 7.5 mg | Centrally read (n=73,71,72,71,70) | 38.0 | 90% Confidence Interval 28.4 to 47.6 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | PF-00547659 22.5 mg | Centrally read (n=73,71,72,71,70) | 54.2 | 90% Confidence Interval 44.2 to 64.2 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | PF-00547659 75 mg | Centrally read (n=73,71,72,71,70) | 45.1 | 90% Confidence Interval 35.0 to 55.3 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | PF-00547659 225 mg | Centrally read (n=73,71,72,71,70) | 50.0 | 90% Confidence Interval 39.6 to 60.4 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | Placebo | Locally read (n=73,70,72,70,70) | 32.9 | 90% Confidence Interval 24.2 to 42.3 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | PF-00547659 7.5 mg | Locally read (n=73,70,72,70,70) | 38.6 | 90% Confidence Interval 28.8 to 48.1 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | PF-00547659 22.5 mg | Locally read (n=73,70,72,70,70) | 54.2 | 90% Confidence Interval 44.2 to 64.2 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | PF-00547659 75 mg | Locally read (n=73,70,72,70,70) | 48.6 | 90% Confidence Interval 38.2 to 59.0 | percentage of participants |
| Percentage of Participants With Clinical Response at Week 12 | PF-00547659 225 mg | Locally read (n=73,70,72,70,70) | 51.4 | 90% Confidence Interval 41.0 to 61.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01620255/results